Contributions
Abstract: EP1738
Type: Poster Sessions
Abstract Category: Therapy - Others
Background and aims: Multiple sclerosis is a progressive disabling disease and the life expectancy is with 5-7 years lower than the normal population, mostly due to the complications or other comorbidities. It is estimated that the long term prognosis is better in the recurrent-relapsing (RR) form than in the secondary ones (SP) due to the fact that they have a better response to immunomodulatory therapy which is what our study is meant to evaluate.
Methods: We have conducted an ambispective observational study based on 450 patients with MS and following immunomodulatory therapy in the Neurology Department of Colentina Clinical Hospital, Bucharest, over a period of 2 years.
Results: Our lot consisted of 450 patients (280 RR and 170 SP) all of them undergoing immunomodulatory therapy (235 interferon, 84 glatiramer acetate, 76 teriflunomide and 55 natalizumab therapy), with EDSS< 3p. 14% of them had other comorbidities before entering the program. By the end of the first year, 10% of the RR lot reached an EDSS=3.5p and 15.2% of the SP. By the end of the second year 8% of the RR patients had an EDDS>4 and 12.9% of the SP. There have been 8 deaths (3 RR, 5 SP), 7 due to comorbidities (5 cardio-vascular events, 2 cases of cancer) and 1 EDSS=10 (SP). The mean of time in which they reached and EDSS=3.5 was 8 months for the RR patients, 6.4 months for SP patients that respected the indicated treatments and 5 months for those who decided to interrupt the therapy in the RR lot, respectively 4 months for SP. The patients who at the end of the 2 year period didn't have an EDSS< 3 reported having a balanced diet, exercising regularly and treating every new episode with corticoids.
Conclusions: There are many factors that influence the life expectancy of MS patients, including the age of onset, the progression rate and the treatment, but the dizability imposed by this pathology isn't necesarly a death cause. There is a sensible difference between the way that RR and SP patients respond to treatment, in favour of the first lot.
Disclosure: Oana Rujan: nothing to disclose
Abstract: EP1738
Type: Poster Sessions
Abstract Category: Therapy - Others
Background and aims: Multiple sclerosis is a progressive disabling disease and the life expectancy is with 5-7 years lower than the normal population, mostly due to the complications or other comorbidities. It is estimated that the long term prognosis is better in the recurrent-relapsing (RR) form than in the secondary ones (SP) due to the fact that they have a better response to immunomodulatory therapy which is what our study is meant to evaluate.
Methods: We have conducted an ambispective observational study based on 450 patients with MS and following immunomodulatory therapy in the Neurology Department of Colentina Clinical Hospital, Bucharest, over a period of 2 years.
Results: Our lot consisted of 450 patients (280 RR and 170 SP) all of them undergoing immunomodulatory therapy (235 interferon, 84 glatiramer acetate, 76 teriflunomide and 55 natalizumab therapy), with EDSS< 3p. 14% of them had other comorbidities before entering the program. By the end of the first year, 10% of the RR lot reached an EDSS=3.5p and 15.2% of the SP. By the end of the second year 8% of the RR patients had an EDDS>4 and 12.9% of the SP. There have been 8 deaths (3 RR, 5 SP), 7 due to comorbidities (5 cardio-vascular events, 2 cases of cancer) and 1 EDSS=10 (SP). The mean of time in which they reached and EDSS=3.5 was 8 months for the RR patients, 6.4 months for SP patients that respected the indicated treatments and 5 months for those who decided to interrupt the therapy in the RR lot, respectively 4 months for SP. The patients who at the end of the 2 year period didn't have an EDSS< 3 reported having a balanced diet, exercising regularly and treating every new episode with corticoids.
Conclusions: There are many factors that influence the life expectancy of MS patients, including the age of onset, the progression rate and the treatment, but the dizability imposed by this pathology isn't necesarly a death cause. There is a sensible difference between the way that RR and SP patients respond to treatment, in favour of the first lot.
Disclosure: Oana Rujan: nothing to disclose